Tweets
#ACR23 Abs #2548 showed incidence rate of uveitis TEAEs was lower to Wk 16 in axSpA pts randomized to BKZ 160 mg Q4W vs PBO. https://t.co/kBLQnJbTU2 @rheumnow https://t.co/regYgvvCts
Dr. Rachel Tate ( View Tweet )
2 years 7 months ago
Bimekizumab is Coming… in 3rd Place
Nearly two dozen bimekizumab abstracts will be featured at #ACR23 and it recently received authorization in Europe and the US for psoriasis.
https://t.co/i2ptDnGr4a https://t.co/rZC6IORm5E
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
#ACR23 Daily Recap - MONDAY
Join our live-stream panel discussion as we dive deep into the highlights and key takeaways from day two of ACR 2023. https://t.co/0WXuV3wzzF
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
ACR2023 Daily Recap - MONDAY
Join our live-stream panel discussion as we dive deep into the highlights and key takeaways from day two of ACR 2023. https://t.co/qOjSd8vuB3
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
Join us tonight at 6pm PT/ 9pm ET for our daily #ACR23 recap. https://t.co/jjcnekqVPe
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty.
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
Early experience w/SGLT2i in SLE (Prof Petri):
👉Reduction of decline in eGFR after SGLT2i
👉Improvement in RUPCR after SGLT2i
BUT observed differences not significant when compared w/prior to starting SGLT2i
Small sample size. Longer ffup needed.
#ACR23 ABST1490 @RheumNow https://t.co/IhVFacRi0g
sheila ( View Tweet )
2 years 7 months ago
Went into more depth on this great topic of IBD in SpA on @RheumNow #ACR23
Should we be screening SpA patients with fecal calprotectin to look for undiagnosed SpA?
https://t.co/TmXhm2MEfO https://t.co/SWJSqF5pkW
Eric Dein ( View Tweet )
2 years 7 months ago
You said that CAR-T needs a #RCT in severe #SLE @RheumNow @ACRheum #ACR23 https://t.co/yilohqz1YE
Janet Pope ( View Tweet )
2 years 7 months ago
Age does NOT affect the chance of getting irAE or the severity when using check point inhibitors to treat cancer. Data from #CANRIO database in #Canada #ACR 23 @ACRheum @RheumNow #1063 https://t.co/bqbiXzdAqr
Janet Pope ( View Tweet )
2 years 7 months ago
#irAE Baseline immune suppression does NOT protect against worsening synovitis flares when using check point inhibitors in Pts with established #inflammatory #arthritis #ACRbest #ACR23 @ACRheum @RheumNow abst1075 Data from #CanRIO database https://t.co/lOCf8Tbgta
Janet Pope ( View Tweet )
2 years 7 months ago
#ACR23 highlights from PlenaryII
🙉#RA #ILD seems that #TNFi is equal to other bDMARDs - was thought to worsen /cause it.
🙉Septra should be given with #rituximab and #steroids in #GCA to prevent #infections not just #PJP
#ACR23 @RheumNow @ACRheum #ACRbest
Janet Pope ( View Tweet )
2 years 7 months ago
